{
    "organizations": [],
    "uuid": "6f741102ebf77fbab06e35c76af5d4c6dc365508",
    "author": "",
    "url": "https://www.reuters.com/article/brief-resverlogix-receives-fda-protocol/brief-resverlogix-receives-fda-protocol-acceptance-for-ongoing-phase-3-betonmace-trial-idUSASB0C0PM",
    "ord_in_thread": 0,
    "title": "BRIEF-Resverlogix Receives FDA Protocol Acceptance For Ongoing Phase 3 Betonmace Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 11 (Reuters) - Resverlogix Corp:\n* RESVERLOGIX RECEIVES FDA PROTOCOL ACCEPTANCE FOR THE ONGOING PHASE 3 BETONMACE TRIAL\n* RESVERLOGIX CORP - BETONMACE TOP LINE DATA IS STILL PLANNED TO BE AVAILABLE AROUND END OF 2018\n* RESVERLOGIX - BETONMACE TRIAL WILL NOW BE EXPANDED TO NORTH AMERICA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-11T16:35:00.000+02:00",
    "crawled": "2018-01-11T16:53:03.023+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "resverlogix",
        "corp",
        "resverlogix",
        "receives",
        "fda",
        "protocol",
        "acceptance",
        "ongoing",
        "phase",
        "betonmace",
        "trial",
        "resverlogix",
        "corp",
        "betonmace",
        "top",
        "line",
        "data",
        "still",
        "planned",
        "available",
        "around",
        "end",
        "resverlogix",
        "betonmace",
        "trial",
        "expanded",
        "north",
        "america",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}